{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T10:26:18Z","timestamp":1772015178271,"version":"3.50.1"},"reference-count":52,"publisher":"Informa UK Limited","issue":"8","content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Pharmaceutical Development and Technology"],"published-print":{"date-parts":[[2024,9,13]]},"DOI":"10.1080\/10837450.2024.2398526","type":"journal-article","created":{"date-parts":[[2024,8,29]],"date-time":"2024-08-29T08:07:39Z","timestamp":1724918859000},"page":"824-831","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":1,"title":["A review on abuse-deterrent formulations: formulation technology and regulatory stands in approval process"],"prefix":"10.1080","volume":"29","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4318-268X","authenticated-orcid":false,"given":"Jaydip","family":"Bhola","sequence":"first","affiliation":[{"name":"Department of Pharmaceutics, Gujarat Technological University, Ahmedabad, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9517-7578","authenticated-orcid":false,"given":"Chetan","family":"Borkhataria","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutics, B. K. Mody Government Pharmacy College, Rajkot, India"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2024,9,3]]},"reference":[{"key":"e_1_3_2_2_1","unstructured":"Alpharma Pharmaceuticals\/King Pharmaceuticals. 2009a. EMBEDA (morphine sulfate and naltrexone hydrochloride) Extended-Release Capsules [Chemistry review]. U.S. Food and Drug Administration. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2009\/022321s000ChemR.pdf."},{"key":"e_1_3_2_3_1","unstructured":"Alpharma Pharmaceuticals\/King Pharmaceuticals. 2009b. EMBEDA (morphine sulfate and naltrexone hydrochloride) Extended-Release Capsules [Summary review]. U.S. Food and Drug Administration. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2009\/022321s000SumR.pdf."},{"key":"e_1_3_2_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2021.120481"},{"key":"e_1_3_2_5_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40268-017-0175-y"},{"key":"e_1_3_2_6_1","unstructured":"CDER-USFDA. 2010. OxyContin (Oxycodone Hydrochloride) Controlled-Release Tablets [Summary review]. U.S. Food and Drug Administration. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2010\/022272s000SumR.pdf."},{"key":"e_1_3_2_7_1","unstructured":"CDER-USFDA. 2015. Guidance for Industry Abuse-Deterrent Opioids\u2014Evaluation and Labeling. (Issue April)."},{"key":"e_1_3_2_8_1","unstructured":"CDER-USFDA. 2017a. Assessment of Abuse Potential of Drugs Guidance for Industry Assessment of Abuse Potential of Drugs Guidance for Industry. (Issue January)."},{"key":"e_1_3_2_9_1","unstructured":"CDER-USFDA. 2017b. General principles for evaluating the abuse deterrence of generic solid oral opioid drug products guidance for industry. (Issue November):1\u201333. https:\/\/www.govinfo.gov\/content\/pkg\/FR-2017-11-22\/pdf\/2017-25248.pdf"},{"key":"e_1_3_2_10_1","unstructured":"Collegium Pharma. 2016a. XTAMPZA ER (oxycodone) Extended-Release Capsules [Printed Labelling]. U.S. Food and Drug Administration. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2016\/208090Orig1s000Lbl.pdf."},{"key":"e_1_3_2_11_1","unstructured":"Collegium Pharma. 2016b. XTAMPZA ER (oxycodone) Extended-Release Capsules [Summary review]. U.S. Food and Drug Administration. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2016\/208090Orig1s000SumR.pdf."},{"key":"e_1_3_2_12_1","doi-asserted-by":"publisher","DOI":"10.1055\/s-2000-7583"},{"key":"e_1_3_2_13_1","unstructured":"Egalet US. 2017a. ARYMO ER (morphine sulfate) Extended-Release Tablets [Chemistry review]. U.S. Food and Drug Administration. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2017\/208603Orig1s000ChemR.pdf."},{"key":"e_1_3_2_14_1","unstructured":"Egalet US. 2017b. ARYMO ER (morphine sulfate) Extended-Release Tablets [Summary Review]. U.S. Food and Drug Administration. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2017\/208603Orig1s000SumR.pdf."},{"key":"e_1_3_2_15_1","unstructured":"European Monitoring Centre for Drugs and Drug Addiction. 2016. Strategies to prevent diversion of opioid substitution treatment medications. https:\/\/www.euda.europa.eu\/topics\/pods\/preventing-diversion-of-opioid-substitution-treatment_en."},{"key":"e_1_3_2_16_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMe1903798"},{"key":"e_1_3_2_17_1","unstructured":"Hirsh J Fleming A Rariy R Klibanov A. 2020. Abuse-Deterrent Drug Formulations (US Patent no.: US 10525052B2). (Patent No. US10525052B2B)."},{"key":"e_1_3_2_18_1","unstructured":"Inspirion Delivery Technologies LLC. 2015a. MORPHABOND (morphine sulfate) [Printed Labelling]. U.S. Food and Drug Administration. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2015\/206544Orig1s000Lbl.pdf."},{"key":"e_1_3_2_19_1","unstructured":"Inspirion Delivery Technologies LLC. 2015b. MORPHABOND (morphine sulfate) [Summary review]. U.S. Food and Drug Administration. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2015\/206544Orig1s000SumR.pdf."},{"key":"e_1_3_2_20_1","unstructured":"Inspirion Delivery Technologies LLC. 2017a. ROXYBOND (oxycodone hydrochloride) Tablets [Printed Labelling]. U.S. Food and Drug Administration. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2017\/209777Orig1s000Lbl.pdf."},{"key":"e_1_3_2_21_1","unstructured":"Inspirion Delivery Technologies LLC. 2017b. ROXYBOND (oxycodone hydrochloride) Tablets [Summary review]. U.S. Food and Drug Administration. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2017\/209777Orig1s000SumR.pdf."},{"key":"e_1_3_2_22_1","doi-asserted-by":"publisher","DOI":"10.1177\/0269881109103113"},{"key":"e_1_3_2_23_1","doi-asserted-by":"publisher","DOI":"10.15171\/apb.2018.058"},{"key":"e_1_3_2_24_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11926-008-0003-z"},{"key":"e_1_3_2_25_1","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.833"},{"key":"e_1_3_2_26_1","volume-title":"Pathways to Prevention Workshop. (Vol. 1)","author":"Lewandowski CM.","year":"2014","unstructured":"Lewandowski CM. 2014. The role of opioids in the treatment of chronic pain. In Pathways to Prevention Workshop. (Vol. 1) https:\/\/prevention.nih.gov\/sites\/default\/files\/documents\/programs\/p2p\/ODPPainPanelStatementFinal_10-02-14.pdf"},{"key":"e_1_3_2_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2016.06.012"},{"key":"e_1_3_2_28_1","doi-asserted-by":"publisher","DOI":"10.2165\/00023210-199605030-00005"},{"key":"e_1_3_2_29_1","doi-asserted-by":"publisher","DOI":"10.1517\/17425255.2015.979786"},{"key":"e_1_3_2_30_1","doi-asserted-by":"publisher","DOI":"10.1208\/s12249-019-1565-y"},{"key":"e_1_3_2_31_1","unstructured":"Ministry of Health Canada. 2016. Tamper-Resistance Formulations of Opioid Drug Products."},{"issue":"4","key":"e_1_3_2_32_1","first-page":"4","article-title":"Substance abuse in india","volume":"1","author":"Nadeem A","year":"2009","unstructured":"Nadeem A, Rubeena B, Agarwal VK, Piyush K. 2009. Substance abuse in india. Pravara Medical Review. 1(4):4\u20136.","journal-title":"Pravara Medical Review"},{"key":"e_1_3_2_33_1","unstructured":"NIDA. 2019. Overdose Death Rates | National Institute on Drug Abuse (NIDA). National Institute on Drug Abuse. https:\/\/www.drugabuse.gov\/drug-topics\/trends-statistics\/overdose-death-rates."},{"key":"e_1_3_2_34_1","unstructured":"Pfizer Inc. 2016a. TROXYCA ER (oxycodone hydrochloride\/naltrexone hydrochloride) [Printed Labelling]. U.S. Food and Drug Administration. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2016\/207621Orig1s000Lbl.pdf."},{"key":"e_1_3_2_35_1","unstructured":"Pfizer Inc. 2016b. TROXYCA ER (oxycodone hydrochloride\/naltrexone hydrochloride) [Summary review]. U.S. Food and Drug Administration. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2016\/207621Orig1s000SumR.pdf."},{"issue":"1","key":"e_1_3_2_36_1","first-page":"11","article-title":"Abuse of psychiatric medications: not just stimulants and benzodiazepines Anticholinergics, antidepressants, antipsychotics, and gabapentinoids may also be subject to misuse or abuse","volume":"18","author":"Pierre JM.","year":"2019","unstructured":"Pierre JM. 2019. Abuse of psychiatric medications: not just stimulants and benzodiazepines Anticholinergics, antidepressants, antipsychotics, and gabapentinoids may also be subject to misuse or abuse. Current Psychiatry. 18 (1):11\u201327.","journal-title":"Current Psychiatry"},{"key":"e_1_3_2_37_1","unstructured":"Purdue Pharma. 2010. OxyContin (Oxycodone Hydrochloride) Controlled-Release Tablets [Printed Labelling]. U.S. Food and Drug Administration. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2010\/022272s000Lbl.pdf."},{"key":"e_1_3_2_38_1","unstructured":"Purdue Pharma. 2014a. Hysingla ER (hydrocodone bitartrate) ER Tablets [Printed Labelling] (pp. 1\u201336). U.S. Food and Drug Administration. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2014\/206627Orig1s000Lbl.pdf."},{"key":"e_1_3_2_39_1","unstructured":"Purdue Pharma. 2014b. Hysingla ER (hydrocodone bitartrate) ER Tablets [Summary review]. U.S. Food and Drug Administration. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2014\/206627Orig1s000SumR.pdf."},{"key":"e_1_3_2_40_1","unstructured":"Purdue Pharma. 2014c. TARGINIQ ER (oxycodone hydrochloride\/naloxone hydrochloride) Extended-Release Tablets [Chemistry review]. U.S. Food and Drug Administration. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2014\/205777Orig1s000ChemR.pdf."},{"key":"e_1_3_2_41_1","unstructured":"Purdue Pharma. 2014d. TARGINIQ ER (oxycodone hydrochloride\/naloxone hydrochloride) Extended-Release Tablets [Printed Labelling]. U.S. Food and Drug Administration. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2014\/205777Orig1s000Lbl.pdf."},{"key":"e_1_3_2_42_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.15420"},{"key":"e_1_3_2_43_1","doi-asserted-by":"publisher","DOI":"10.4103\/0253-7176.106038"},{"key":"e_1_3_2_44_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13181-012-0270-y"},{"key":"e_1_3_2_45_1","doi-asserted-by":"publisher","DOI":"10.2165\/11530800-000000000-00000"},{"key":"e_1_3_2_46_1","unstructured":"Stinchcomb AL Golinski MJ Hammell DC Howard JL. 2009. Transdermally deliverable opioid prodrugs Abuse-resistant compositions and Methods of using opioid prodrugs. (Patent No. US 7511054 B2)."},{"key":"e_1_3_2_47_1","unstructured":"Substance Abuse and Mental Health Searvices Admintration. (2022). National demographics of non-fatal overdoses. In Drug Abuse Warning Network. https:\/\/www.samhsa.gov\/data\/sites\/default\/files\/reports\/rpt39474\/Non-Fatal%20Overdoses%20Short%20Report%20Mar22%20Final.pdf"},{"key":"e_1_3_2_48_1","doi-asserted-by":"publisher","DOI":"10.2147\/SAR.S37917"},{"key":"e_1_3_2_49_1","unstructured":"Teva Brand Pharmaceutical. 2017. VANTRELA ER (hydrocodone bitartrate) Extended-Release Tablets [Printed Labelling]. U.S. Food and Drug Administration. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2017\/207975Orig1s000Lbl.pdf."},{"key":"e_1_3_2_50_1","unstructured":"Teva Branded Pharmaceutical. 2017. VANTRELA ER (hydrocodone bitartrate) Extended-Release Tablets [Chemistry review]. U.S. Food and Drug Administration. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2017\/207975Orig1s000ChemR.pdf."},{"key":"e_1_3_2_51_1","unstructured":"Therapeutic Goods Administration. 2018. Consultation paper - Prescription strong (Schedule 8) opioid use and misuse in Australia \u2013 options for a regulatory response. Therapeutic Goods Administration. https:\/\/www.tga.gov.au\/sites\/default\/files\/consultation-prescription-strong-schedule-8-opiod-use-misuse-in-australia-options-for-regulatory-response.pdf"},{"key":"e_1_3_2_52_1","unstructured":"Food and Drug Administration Amendments Act of 2007. 2007. U.S. Food and Drug Administration. https:\/\/www.govinfo.gov\/app\/details\/PLAW-110publ85"},{"key":"e_1_3_2_53_1","first-page":"1","article-title":"Understanding abuse deterrent opioids","author":"Winiecki SK.","year":"2016","unstructured":"Winiecki SK. 2016. Understanding abuse deterrent opioids. CDER Office of Communication, Division of Drug Information (DDI) Webinar, 1\u201336. https:\/\/www.fda.gov\/files\/about%20fda\/published\/Understanding-Abuse-Deterrent-Opioids-%28PDF---343KB%29.pdf","journal-title":"CDER Office of Communication, Division of Drug Information (DDI) Webinar"}],"container-title":["Pharmaceutical Development and Technology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/10837450.2024.2398526","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,16]],"date-time":"2024-10-16T17:44:07Z","timestamp":1729100647000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/10837450.2024.2398526"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,3]]},"references-count":52,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2024,9,13]]}},"alternative-id":["10.1080\/10837450.2024.2398526"],"URL":"https:\/\/doi.org\/10.1080\/10837450.2024.2398526","relation":{},"ISSN":["1083-7450","1097-9867"],"issn-type":[{"value":"1083-7450","type":"print"},{"value":"1097-9867","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,3]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iphd20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iphd20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2024-04-22","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-08-23","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-08-27","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-09-03","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}